

Special Article - Chronic Myeloid Leukemia

Prognosis of Chronic Myeloid Lymphoma with Red Cell Distribution Width

Khani MA^{1*} and Karimi Z²¹Department of Medicine, Najafabad Branch, Islamic Azad University, Iran²Bushehr University of Medical Sciences, Iran***Corresponding author:** Maryam Allahverdi Khani, Islamic Azad University of Medical Sciences, Pouryayeh Vali Blvd, Najafabad, Isfahan, Iran**Received:** June 20, 2018; **Accepted:** June 27, 2018;**Published:** July 04, 2018

Editorial

Cancer is one of the leading causes of mortality in the world and is increasing every year, as of 2017, 600920 deaths due to cancer were reported in the United States [1,2]. So it is necessary to prognosticate these diseases.

Some simple parameters, automatically reported by laboratory blood analyzers, can have multiple clinical applications; for example, Red cell distribution width (RDW) is regularly evaluated as part of a Complete Blood Count (CBC) for collecting information from circulatory evaluations. RDW represents the abnormal survival of red blood cells and it has a high Negative Predictive Value (NPV) to diagnose all types of disorders; it may be useful to evaluate the short-term and long-term prognosis. Recently, RDW has been widely recognized to have an important role in carcinogenesis, tumor progression, and prognosis [3,4]. RDW has been reported as an inflammatory marker for systemic inflammatory response in many diseases. This parameter has been studied as a prognostic factor and an indicator of disease activity in many malignancies; these studies are mainly conducted in cardiovascular diseases and have been studied in very low hematological diseases.

In hematological malignancies such as Chronic Myelogenous Leukemia (CML) who some patients have unfavorable prognosis after treatment and it is extremely variable. Many prognostic factors are used to predict clinical outcome to date treatment response indicated by cytogenetic or molecular evaluation.

There have been few but valuable studies in this regard. Zack and colleagues concluded in their study that RDW increases in Hairy

Cell Leukemia (HCL), which is related to the activity of the disease and becomes normal after treatment [1,3]. In a study, examined the significance of RDW in patients with CML that an important role in the classification of patients to predict the responses and treatment outcomes; In fact, the RDW value in CML patients is higher than normal in most cases, it may predict the treatment response, this type of classification facilitates the planning of treatment [5]. Along with the studies that confirmed a significant association between RDW and an increased risk of cancer and hematology, a study showed that RDW is stable and does not represent time-prognosis [6].

Investigating the relationship between RDW and mutations and prognosis of patients may provide a new insight into the treatment of CML. It's suggested that in the future, the findings should be considered in larger groups, and in different treatment categories.

References

1. Shahriari M, Jafari M, Khalafi M, Ramezani M, Maki M, Soleimani FH, et al. Pre-and Post-birth Causes of Acute Lymphoblastic Leukemia. *International Journal of Cancer Management*. 2018.
2. Amori N, Aghajani M, Asgarian F, Jazayeri M. Epidemiology and trend of common cancers in Iran (2004-2008). *European journal of cancer care*. 2017; 26.
3. Periša V, Zibar L, Sinčić-Petričević J, Knezović A, Periša I, Barbić J. Red blood cell distribution width as a simple negative prognostic factor in patients with diffuse large B-cell lymphoma: a retrospective study. *Croatian medical journal*. 2015; 56: 334-343.
4. Riedl J, Posch F, Königsbrügge O, Lötsch F, Reitter EM, Eigenbauer E, et al. Red cell distribution width and other red blood cell parameters in patients with cancer: association with risk of venous thromboembolism and mortality. *PLoS one*. 2014; 9: e111440.
5. Iriyama N, Hata Y, Kobayashi S, Uchino Y, Miura K, Kurita D, et al. Higher red blood cell distribution width is an adverse prognostic factor in chronic-phase chronic myeloid leukemia patients treated with tyrosine kinase inhibitors. *Anticancer research*. 2015; 35: 5473-5478.
6. Montagnana M, Danese E. Red cell distribution width and cancer. *Annals of translational medicine*. 2016; 4.